A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia.
Vergne-Salle
Pascale
P
Pain Center and Department of Rheumatology, University Hospital of Limoges, Limoges, France. pascale.vergne-salle@chu-limoges.fr
Dufauret-Lombard
Carine
C
Bonnet
Christine
C
Simon
Anne
A
Trèves
Richard
R
Bonnabau
Henri
H
Bertin
Philippe
P
D000293:Adolescent; D000328:Adult; D000368:Aged; D002908:Chronic Disease; D004311:Double-Blind Method; D005356:Fibromyalgia / Q000188:drug therapy*; D005500:Follow-Up Studies; D006801:Humans; D007211:Indoles / Q000008:administration & dosage* / Q000009:adverse effects; D007275:Injections, Intravenous; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy*; D010919:Placebos; D011446:Prospective Studies; D011788:Quality of Life; D011807:Quinolizines / Q000008:administration & dosage* / Q000009:adverse effects; D058831:Serotonin 5-HT3 Receptor Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome; D055815:Young Adult
D007211:Indoles; D010919:Placebos; D011807:Quinolizines; D058831:Serotonin 5-HT3 Receptor Antagonists; C060344:dolasetron